Posted by Michael Wonder on 27 Feb 2023
Areteia Therapeutics granted ILAP designation from UK MHRA for oral dexpramipexole for eosinophilic asthma
23 February 2023 - Areteia Therapeutics today announced that the UK’s MHRA has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase 3 clinical development.
Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels.
